Xtant Medical Receives Going Concern Opinion Belgrade, MT

Medical Receives Going Concern Opinion

Belgrade, MT, April 05, 2017 (GLOBE

NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products

and medical devices, today announced that as previously disclosed in its Annual Report on Form 10-K for the year ended December

31, 2016, which was filed on March 29, 2017 with the Securities and Exchange Commission, its audited financial statements contained

a going concern qualification paragraph in the audit opinion from its independent registered public accounting firm. See further

discussion in the Company's consolidated financial statements included in the Company's Annual Report on Form 10-K. This announcement

is made pursuant to NYSE MKT Company Guide Section 610(b), which requires public announcement of the receipt of an audit opinion

containing a going concern paragraph. This announcement does not represent any change or amendment to the Company's consolidated

financial statements or to its Annual Report on Form 10-K for the year ended December 31, 2016.

About Xtant Medical Holdings

Xtant Medical Holdings,

Inc. (NYSE MKT:XTNT) develops, manufactures and markets class-leading regenerative medicine products and medical devices for domestic

and international markets. Xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics

for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment

of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. With core competencies

in both biologic and non-biologic surgical technologies, Xtant can leverage its resources to successfully compete in global neurological

and orthopedic surgery markets. For further information, please visit www.xtantmedical.com.

Important Cautions Regarding Forward-Looking

This press release contains certain disclosures that may be deemed

forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to significant

risks and uncertainties. Forward-looking statements include statements that are predictive in nature, that depend upon or refer

to future events or conditions, or that include words such as "continue," "efforts," "expects,"

"anticipates," "intends," "plans," "believes," "estimates," "projects,"

"forecasts," "strategy," "will," "goal," "target," "prospects," "potential,"

"optimistic," "confident," "likely," "probable" or similar expressions or the negative

thereof. Statements of historical fact also may be deemed to be forward-looking statements. We caution that these statements by

their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors,

including, among others: the ability to comply with covenants in the Company's senior credit facility and to make deferred

interest payments; the ability to maintain sufficient liquidity to fund operations; the ability to remain listed on the NYSE MKT;

the ability to obtain financing on reasonable terms; the ability to increase revenue; the ability to continue as a going concern;

the ability to maintain sufficient liquidity to fund operations; the ability to achieve expected results; the ability to remain

competitive; government regulations; the ability to innovate and develop new products; the ability to obtain donor cadavers for

products; the ability to engage and retain qualified technical personnel and members of the Company's management team; the

availability of Company facilities; government and third-party coverage and reimbursement for Company products; the ability to

obtain regulatory approvals; the ability to successfully integrate recent and future business combinations or acquisitions; the

ability to use net operating loss carry-forwards to offset future taxable income; the ability to deduct all or a portion of the

interest payments on the notes for U.S. federal income tax purposes; the ability to service Company debt; product liability claims

and other litigation to which we may be subjected; product recalls and defects; timing and results of clinical studies; the ability

to obtain and protect Company intellectual property and proprietary rights; infringement and ownership of intellectual property;

the ability to remain accredited with the American Association of Tissue Banks; influence by Company management; the ability to

pay dividends; and the ability to issue preferred stock; and other factors.

Additional risk factors are listed

in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q under the heading "Risk Factors." The

Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances

after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.